Gofen & Glossberg LLC IL Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Gofen & Glossberg LLC IL lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 387,103 shares of the company’s stock after buying an additional 17,737 shares during the quarter. Merck & Co., Inc. makes up 1.1% of Gofen & Glossberg LLC IL’s holdings, making the stock its 29th largest holding. Gofen & Glossberg LLC IL’s holdings in Merck & Co., Inc. were worth $32,586,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its holdings in Merck & Co., Inc. by 1.9% in the 3rd quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock valued at $528,000 after acquiring an additional 119 shares during the last quarter. Stillwater Investment Management LLC increased its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after buying an additional 120 shares during the last quarter. Southeast Asset Advisors Inc. increased its holdings in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock worth $449,000 after buying an additional 120 shares during the last quarter. Pinnacle Bank increased its holdings in shares of Merck & Co., Inc. by 6.1% in the 3rd quarter. Pinnacle Bank now owns 2,120 shares of the company’s stock worth $178,000 after buying an additional 122 shares during the last quarter. Finally, Pensionmark Financial Group LLC increased its holdings in shares of Merck & Co., Inc. by 4.2% in the 2nd quarter. Pensionmark Financial Group LLC now owns 3,057 shares of the company’s stock worth $258,000 after buying an additional 124 shares during the last quarter. Institutional investors own 74.97% of the company’s stock.

MRK has been the topic of a number of research reports. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They issued an “outperform” rating and a $103.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a report on Friday, June 14th. Finally, Argus boosted their target price on shares of Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $93.29.

Shares of MRK stock traded down $0.23 during trading hours on Thursday, reaching $83.95. 2,883,879 shares of the stock were exchanged, compared to its average volume of 8,735,727. Merck & Co., Inc. has a 12-month low of $66.10 and a 12-month high of $87.35. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The company’s 50-day moving average price is $84.62 and its 200-day moving average price is $82.22. The firm has a market capitalization of $216.07 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 1.71 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. During the same period in the previous year, the company earned $1.06 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts expect that Merck & Co., Inc. will post 4.92 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.62%. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

In related news, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Why is the conference call important?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.